Company engaged patients diagnosed with chronic babesiosis via social media in a nationwide naming competition A $5K donation from the Company was split between ILADEF and GLA to recognize the winning ...
FREE Study to evaluate the efficacy and safety of ARAKODA® (tafenoquine) for treatment of chronic babesiosisData support ...
Degrees Pharmaceuticals (SXTP) announced that infection with Babesia, a parasite that causes the emerging tick-borne illness called babesiosis, ...
60 Degrees Pharmaceuticals (SXTP) announced results of an insurance claims analysis related to babesiosis and chronic fatigue, as conducted by Komodo Health. Results showed approximately 25,000 ...
90-day trial will measure change in general fatigue in patients with chronic babesiosis following tafenoquine treatment Study will run approximately 12 months and enroll up to 100 patients Internal ...
WASHINGTON - 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) announced Thursday that its Phase 2 trial for chronic babesiosis will be named B-FREE Chronic Babesiosis Study, following a nationwide ...
The company also announced that its Phase 2 trial for chronic babesiosis will be named the B-FREE Chronic Babesiosis Study. This trial, set to begin in early November, will assess the efficacy and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback